AndhraNews.net
Home » Features » Companies » GlaxoSmithKline

GlaxoSmithKline


About GlaxoSmithKline

GlaxoSmithKline is a global pharmaceutical company.

GlaxoSmithKline Biologicals committed US$1.3 million in vaccine and process development with Singapore's Bioprocessing Technology Institute (BTI).

GlaxoSmithKline in News

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Capstone Turbine Corporation of Class Action Lawsuit and Upcoming Deadline - CPST
Pomerantz LLP announces that a class action lawsuit has been filed against Capstone Turbine Corporation ("Capstone" or the "Company") (NASDAQ: CPST) and certain of its officers

Theravance Biopharma Submits Investigational New Drug (IND) Application for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of TD-1473, a novel, potent, and orally administered GI-targeted pan-Janus kinase (JAK) inhibitor

Fish & Richardson Announces Two Principals Named "Litigation Trailblazers" for 2015 by The National Law Journal
Fish & Richardson today announced that Jonathan E. Singer and Ann Cathcart Chaplin have been named "Litigation Trailblazers" by The National Law Journal (NLJ). According to the NLJ, these trailblazers have "shown a deep passion and perseverance in pursuit of their mission, having achieved remarkable successes along the way."

Theravance, Inc. Announces Preliminary Results of Tender Offer
Theravance, Inc. (NASDAQ: THRX) today announced the preliminary results of its "modified Dutch auction" tender offer, which expired at 5:00 P.M., New York City time, on Tuesday, December 1, 2015

Diaceutics Group Names Steve Vitale Managing Director of Analytics, Insights and Strategy Division
Diaceutics Group, a dedicated integrator in personalized and precision medicine, enabling the effective combination of therapies and diagnostics into the treatment pathway, today announced industry veteran Steve Vitale has joined the company to lead its Analytics, Insights and Strategy (AIS) division. Mr

CORRECTION - Enterprise Strategies Announces Formal UK and Central European Expansion With Strategic Hire

Addition to Consulting Team Supports Rapid International Growth and Client Success
LONDON, UNITED KINGDOM--(Marketwired - November 17, 2015) - Enterprise Strategies, a consultancy committed to Delivering the Future of Workâ„  through practical digital strategies and adoption programs, today announced the hiring of Lesley Crook as their Internal Digital Strategy Advisor

Change the Equation Member Companies Pledge 25 Percent Increase in Skills-Based Volunteering by STEM Professionals
WASHINGTON, DC--(Marketwired - November 10, 2015) - Today, at the White House Summit on Next Generation High Schools, Change the Equation announced that 13 of its member companies are committing to a collective 14,000 days of skills-based volunteering in 2016

Texas Round-Up: Lone Star State Ropes in More Than $4 Billion in Active Capital Project Investment From Pharmaceutical-Biotech Sector, an Industrial Info News Alert
Reported by Annette Kreuger, Industrial Info Resources, Incorporated (Sugar Land, Texas)--While more commonly known as the land where oil and chemical industry workers roam, Texas is steadily becoming home to a growing number of scientists from the pharmaceutical and biotech fields

Theravance to Present at Two Upcoming Investor Conferences in November
Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, will present at two upcoming conferences in November 2015:

Sirona Biochem Retains Strategic Advisor to Commercialize Glycoproteins
VANCOUVER, BC--(Marketwired - November 03, 2015) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the "Company") is pleased to announce that it has retained Dr. Mason Ross as a strategic advisor to the Company

Theravance, Inc. Announces Commencement of Self-Tender Offer for up to $75,000,000 of Its Common Stock
Theravance, Inc. (NASDAQ: THRX) today announced that it is commencing its previously announced "modified Dutch auction" tender offer for up to $75,000,000 of its common stock at a price per share not less than $8.50 and not greater than $9.25. The tender offer will expire at 5:00 P.M., New York City time, on Tuesday, December 1, 2015, unless extended by the company

Theravance Reports Third Quarter 2015 Financial Results
Theravance, Inc. (NASDAQ: THRX) today reported financial results for the third quarter ended September 30, 2015. Royalties from sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® earned from Glaxo Group Limited (GSK) during the third quarter of 2015 were $16.8 million, a quarter-over-quarter increase of 21 percent compared to the second quarter of 2015

Theravance Biopharma and Trek Therapeutics Announce Initiation of Phase 2a Trial of TD-6450, an NS5A Inhibitor to Treat Hepatitis C
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Trek Therapeutics ("TREKtx") today announced that TREKtx has initiated a Phase 2a clinical trial of TD-6450, a next-generation investigational NS5A inhibitor in development to treat patients with hepatitis C virus (HCV)

Interim Report January - September 2015
»» Net profit increased by 66 per cent to SEK 1,482 million (892), corresponding to SEK 1.35 (0.81) per ordinary share.

Theravance to Report Third Quarter 2015 Financial Results on October 28, 2015
Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the quarter ended September 30, 2015 after market close on Wednesday, October 28, 2015.

Data From New Retrospective Studies of VIBATIV(R) (Telavancin) Demonstrate Positive Clinical Outcomes for Patients With Difficult-to-Treat, Gram-Positive Infections, Including MRSA
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced new positive data from multiple retrospective studies of VIBATIV® (telavancin) demonstrating positive clinical outcomes for patients with Staphylococcus aureus (S. aureus) bacteremia and methicillin-resistant S. aureus (MRSA) osteomyelitis following treatment with VIBATIV

Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years
Novartis International AG /Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Endonovo Therapeutics Announces Immunotronic and Cytotronic Platforms
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), an innovative biotechnology company developing bioelectronic products and therapies for regenerative medicine, announced two bioelectronic-based platforms for regenerative medicine.

Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL)
Business Wire IndiaSeattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the companies have achieved completion of target patient enrollment in the phase 3 ECHELON-1 clinical trial

Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump(R) Sodium Oxybate
Flamel Technologies (NASDAQ: FLML) today announced that its second clinical study in healthy volunteers using its proprietary Micropump® technology applied to sodium oxybate has achieved the objective of one single dose before bedtime for patients suffering from narcolepsy, confirming the results of a previous, first-in-man, study

Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVie
Mechelen, Belgium; 19 December 2014 - Galapagos NV (Euronext: GLPG) announces the initiation of the first Phase 1 study with GLPG1837. This novel potentiator is designed as a CFTR targeted therapy for cystic fibrosis (CF) patients who carry class III/IV mutations (e.g., G551D)

BrightScope Announces Its Sixth Annual Top 30 401k Plans List
BrightScope (www.brightscope.com), a leading provider of independent financial information and investment research, is proud to announce the sixth BrightScope year-end ranking of the Top 30 401k Plans List to recognize companies with the best 401k plans containing more than $1 billion in assets.

Flamel Technologies Transfers Intangible Property to Irish-Based Subsidiary in Global Reorganization
Flamel Technologies (NASDAQ: FLML) announced today that it is moving all intangible property from its French entity to its Irish-based entity as a part of a global reorganization. The intangible property includes patents on its drug delivery platform technologies, clinical data sets and other intangible assets related to its pipeline of proprietary products in development

Galapagos regains full rights to GPR84 inhibitor GLPG1205
Program to enter first Phase 2 patient study in ulcerative colitis this month

Flamel Technologies to Be Included in NASDAQ Biotech Index
Flamel Technologies (NASDAQ: FLML) announced today that its common stock has been selected for inclusion in the NASDAQ Biotechnology Index (NBI), effective before market open on Monday, December 22, 2014

Galapagos selects second component of its investigational cystic fibrosis combination treatment

REMINDER: Theravance Biopharma to Host Investor and Analyst Day on December 12th
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., a reminder that the Company will host an Investor and Analyst Day for the investment community on Friday, December 12, 2014 from 8:30 am to 11:30 am EST in New York, NY

Theravance Biopharma Announces New Employment Inducement Awards
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that stock options to purchase an aggregate of 104,800 of the Company's ordinary shares were granted to ten new non-executive officer employees on December 1, 2014

Flamel Technologies Closes Sale of Development and Manufacturing Facility in Pessac, France to Recipharm AB
Flamel Technologies (NASDAQ: FLML) announced today that it has closed the sale of its development and manufacturing facility located in Pessac, France, to Recipharm AB that was announced on November 28, 2014. Under the agreement, Recipharm paid Flamel EUR 10.6 million and made an investment of EUR 10.5 million in Flamel's stock at a purchase price equal to the trailing 20-day average price.

Flamel Technologies Sells Development and Manufacturing Facility in Pessac, France to Recipharm AB
Flamel Technologies (NASDAQ: FLML) announced today that it has entered into an agreement to divest its development and manufacturing facility located in Pessac, France, to Recipharm AB. Under the agreement, Recipharm will pay Flamel EUR 10.6 million and make an investment of EUR 10.5 million in Flamel's stock upon the closing of deal at a purchase price equal to the trailing 20-day average price

Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA
Mechelen, Belgium; 24 November 2014:Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines, announces that recruitment of rheumatoid arthritis (RA) patients for the Darwin 2 study with GLPG0634 has been completed

Theravance Biopharma to Host Investor and Analyst Day on December 12th
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that the Company will host an Investor and Analyst Day for the investment community on Friday, December 12, 2014 from 8:30 am to 11:30 am EST in New York, NY

ABLYNX APPOINTS JOHAN HEYLEN AS CHIEF COMMERCIAL OFFICER
GHENT, Belgium, 18 November 2014 - Ablynx [Euronext Brussels: ABLX] today announced the appointment of Johan Heylen as Chief Commercial Officer. Mr Heylen will assume responsibility for all Ablynx's commercial activities

Galapagos presents clean drug-drug interaction profile with GLPG0634 (filgotinib) at ACR 2014
Mechelen, Belgium 17 November 2014: Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines, announces that it will present data supporting the safe use and absence of drug-drug interactions of GLPG0634 (filgotinib) with drugs commonly prescribed for rheumatoid arthritis (RA) patients

Theravance Biopharma to Present at the Stifel Healthcare Conference on November 18th
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that Rick E Winningham, Theravance Biopharma's chief executive officer, is scheduled to present at the Stifel Healthcare Conference on Tuesday, November 18, 2014, at 9:45 a.m. EST

Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA
Mechelen, Belgium 12 November 2014:Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines, announces that recruitment of rheumatoid arthritis (RA) patients for the Darwin 1 Phase 2B study with GLPG0634 has been completed.

Berkeley Research Groups Adds Healthcare and Life Sciences Compliance and Risk Management Experts
Berkeley Research Group has expanded its team of top healthcare and life sciences compliance professionals with the additions of Rosemary Weghorst as a director and Katherine Norris as a principal in the firm's Washington, DC, office.

Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
Seattle Genetics, Inc

Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) has announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL)

Historic 6th Annual Pharmaceutical Leadership Summit and Pharmaleaders Awards 2013 Focused to Give Aam Admi of India Affordable Medicines and Quality Healthcare
In a sequel to the sixty days of the voting by the Indian masses to select the best of the best in the final five nominees in various important categories & individual nonvoting categories, Pharmaleaders (www.pharmaleaders

Noted Healthcare Industry Experts and Medical Professionals to Receive Pharmaleaders 2013 Power Brand Awards
In an era where Healthcare in India is the most neglected as Politicians & Policy Makers are busy scoring their political points, Pharmaleaders attempt to raise the uncomfortable questions ignored by other media houses as we believe that healthcare is key to the nation development & India cannot be a mute spectator where policy reforms in healthcare has taken a backstage over political issues

GSK Announces New Rs. 864 crore [£85million] Pharmaceutical Manufacturing Investment in India
A new Rs. 864 crore [£85million] factory creating 250 jobs in India was today announced by healthcare company GlaxoSmithKline (GSK) as part of its continued commitment to ensuring access to medicines for people in the country

ANORO(TM) ELLIPTA(TM) Approved as First Once-Daily Dual Bronchodilator for the Treatment of COPD in the US
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc

BrightScope Announces Its Fifth Annual Year-End Top 30 401k Plans List
BrightScope (www.brightscope.com), the leading provider of independent retirement plan ratings and investment research, is proud to announce the fifth annual BrightScope Year-End Top 30 Ratings List covering 401k plans with more than $1 billion in assets

Galapagos selects pre-clinical candidate for cystic fibrosis
Novel potentiator shows more activity in pre-clinical studies than market leader Kalydeco® Start of Phase 1 expected before end 2014 Mechelen, Belgium; 16 December 2013 - Galapagos NV (Euronext: GLPG) announced today that it nominated a pre-clinical candidate potentiator for clinical development in its cystic fibrosis (CF) program.

Letter to Islet Sciences, Inc. (ISLT) Shareholders From CEO James Green
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT)

Boston Therapeutics Appoints Three to Management Positions
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Edward Shea as Vice President Business Development, Tina M. Gagnon as Consulting Director of Finance, and Yael T. Bobruff, Ph.D. as Clinical Affairs Manager, effective immediately.

GSK and Theravance Announce Positive Results From Pivotal Phase III Study for Fluticasone Furoate/Vilanterol in Asthma
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from a phase III efficacy and safety study of fluticasone furoate "FF"/vilanterol "VI" designed to support a potential filing for an asthma indication for adults in the US.

Flamel Technologies Announces $15 Million Line of Credit
Flamel Technologies (NASDAQ: FLML) today announced that it established a USD $15.0 million secured line of credit with Broadfin Capital, a current Flamel shareholder. The $15.0 million credit facility can be drawn in three tranches of $5.0 million each. The Company will draw $5.0 million initially and can draw up to two additional $5

Galapagos reports positive Phase 1 results for GLPG1205
Mechelen, Belgium; 4 December 2013 - Galapagos NV (Euronext: GLPG) announced today that GLPG1205, a first-in-class molecule for inflammatory disorders, has demonstrated target engagement, a good safety profile, and favorable drug properties in a Phase 1 study.Galapagos is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.

Galapagos announces GSK2586184 JAK1 molecule moves into Phase 2 for ulcerative colitis
Mechelen, Belgium; 27 November 2013 - Galapagos NV (Euronext: GLPG) announced today that GlaxoSmithKline plan to initiate an exploratory Phase 2 study with GSK2586184 (formerly GLPG0778) in patients with ulcerative colitis, a third indication for this investigational molecule, in addition to psoriasis and lupus.

United Nations, International Aid Organizations Join David Guetta to Launch 'One Voice' Video
International music star David Guetta, together with the United Nations and international aid organizations tonight launched a music video for the new track 'One Voice', in support of "The World Needs More___" campaign to raise funds for humanitarian emergencies. The track and video were penned and performed for the campaign by music artist Mikky Ekko.

Theravance to Present at the 25th Annual Piper Jaffray Healthcare Conference
Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the 25th Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2013, at 9:30 a.m. EST. The conference will be held from December 3-4, 2013 at The New York Palace, New York City, New York.

Geometry Global Welcomes Laura Johnston and John Munyan to Creative Team
WPP's Geometry Global, the largest and most geographically complete activation agency in the world, announced today the joining of Laura Johnston and John Munyan to the agency's Chicago and San Francisco offices respectively.

Galapagos announces that BioFocus has signed an integrated drug discovery collaboration with Boehringer Ingelheim
Mechelen, Belgium, 20 November 2013 - Galapagos (Euronext: GLPG) announced today that its BioFocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim.  Under the terms of the agreement, BioFocus will apply its extensive drug discovery services to an undisclosed target within Boehringer Ingelheim's drug discovery portfolio.

RELVAR(R) ELLIPTA(R) Receives European Marketing Authorisation for the Treatment of Asthma and COPD
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced today that the European Commission has granted marketing authorisation for RELVAR® ELLIPTA®, which is now licensed across 31 European countries for the following uses:

MusclePharm Third Quarter Gross Sales Increased 51% to a Record $31.1 Million
MusclePharm Corporation (OTCQB: MSLP) (the "Company", or "MusclePharm"), a leading international, award-winning sports nutrition company, announced today its financial results for the third quarter ended September 30, 2013 ("Q3 2013").

GSK Initiates Voluntary Open Offer to Increase Stake in its Pharmaceuticals Subsidiary in India
GlaxoSmithKline (“GSK”) (LSE: GSK) today announced a Voluntary Open Offer (the “Offer”) to increase its stake in its publicly-listed pharmaceuticals subsidiary in India (GlaxoSmithKline Pharmaceuticals Limited, the “Company”) from 50.7% to up to 75% at a price of INR 3,100 per share

Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
Seattle Genetics, Inc

Market for Kinase Inhibitors Heats Up: Kalorama
The cancer kinase inhibitor market is estimated at $12.1 billion worldwide for 2012, representing annual revenue growth of 16.9% over 2007. The effectiveness of kinase inhibitors has sparked interest from major pharmaceutical companies, according to the healthcare market research publisher, Kalorama Information

GSK and Theravance Announce Regulatory Submission for UMEC/VI (LAMA/LABA) in the US
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application in the US for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD).

Pharma-Biotech Industry Invests More Than $12 Billion in 2012 North American Project Starts, an Industrial Info News Alert
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- As the last moments of 2012 run their course, it is a good time to take a look at the Pharmaceutical-Biotech Industry's capital and maintenance (MRO) project activity for the year. In January, the industry had a whopping $17 billion worth of projects set to launch construction in 2012

As Competitors Pursue Alternatives Medgenics' INFRADURE Gains Prominence for its Potential to Treat Hepatitis
Medgenics' (NYSEAMEX: MDGN) INFRADURE(TM) provides sustained productionand delivery of interferon-alpha for the treatment of hepatitis. INFRADURE(TM) is a kind of miniature pump that is impacted into the patient and continuously produces and release the desired protein into the patient's system

United States Diagnostics Standards (USDS) Appoints Christopher Singer as CEO
United States Diagnostics Standards (USDS), the independent review body for medical diagnostics, today announced that it has appointed Christopher Singer to serve as CEO

Brands Take Centre Stage at the Festival of Media Asia 2013
The Festival of Media Asia, the Asian iteration of the acclaimed Festival of Media for creativity and innovation, today announced an impressive line-up of speakers who will be participating in next year's event, held at the W Singapore - Sentosa Cove from 3-5 March 2013 in Singapore. The list features an array of global and Asian brand leaders, providing the much-needed brand perspective

Theravance Announces Initiation of Phase 2b Study With Its LAMA Candidate, TD-4208, for the Treatment of COPD
Theravance, Inc. (NASDAQ: THRX) announced the initiation of a dose ranging Phase 2b study with TD-4208 as a nebulized aqueous solution in patients with moderate to severe COPD. TD-4208 is an investigational inhaled long-acting muscarinic antagonist (LAMA), discovered using Theravance's multivalent approach to drug design

BrightScope Announces Its Fourth Annual Year-End Top 30 401k Plans List
BrightScope (www.brightscope.com), the leading provider of independent retirement plan ratings and investment research, is proud to announce the fourth annual BrightScope Year-End Top 30 Ratings List covering 401k plans with more than $1 billion in assets

Theravance Announces Initiation of Phase 2 Study With TD-9855 for the Treatment of Fibromyalgia
Theravance, Inc. (NASDAQ: THRX) announced today the initiation of a fibromyalgia Phase 2 study with TD-9855, the lead compound in Theravance's Monoamine Reuptake Inhibitor program

Theravance Reports Favorable Outcome of FDA Advisory Committee Meeting on VIBATIV(R) (telavancin) for the Treatment of Nosocomial Pneumonia
Theravance, Inc. (NASDAQ: THRX) today announced a favorable outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) meeting on VIBATIV® (telavancin) for the treatment of nosocomial pneumonia (NP) due to susceptible isolates of Gram-positive microorganisms.

New Solutions Decrease Risk of Colorectal Surgical Site Infection
A project to reduce colorectal surgical site infections (SSIs) saved more than $3.7 million in costs for 135 avoided SSIs. The two-and-a-half year project included seven hospitals and was directed by the Joint Commission Center for Transforming Healthcare in collaboration with the American College of Surgeons.

Theravance Announces Posting of Briefing Documents for FDA Anti-Infective Drugs Advisory Committee Meeting on VIBATIV(R) (telavancin)
Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has posted on its website briefing documents for the November 29, 2012 Anti-Infective Drugs Advisory Committee (AIDAC) meeting

Outotec appoints Kirsi Nuotto to Executive Board
OUTOTEC OYJSTOCK EXCHANGE RELEASE  NOVEMBER 21, 2012 at 2:00 PM

Starfish Ventures Invests $2.0M in Australian Email and Web Communications Company Atmail

Biota Pharmaceuticals Announces Appointment of New Executive Officers
Biota Pharmaceuticals, Inc. (NASDAQ: BOTA) today announced the appointment of Russell H. Plumb as its Chief Executive Officer and Joseph M. Patti, M.S.P.H., Ph.D. as Executive Vice President, Corporate Development & Strategy. Mr. Plumb will also join the Board of Directors.

Alacris Theranostics enters agreement with GSK to use ModCell (TM) System for early stage cancer research
Alacris Theranostics GmbH /Alacris Theranostics enters agreement with GSK to use ModCell (TM) System for early stage cancer research . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Scientists and Clinicians Collaborate on 8 Projects to Better Understand and Treat Diseases Prevalent in Asia
Singapore announces 8 biomedical sciences research programmes to advance understanding and treatment of diseases especially prevalent amongst the Asian population. These programmes will see biomedical scientists and clinicians working collaboratively to bring about greater healthcare benefits to society and create economic growth for Singapore

NYU Stern Hosts Inaugural India Business Forum on January 11, 2013
On January 11, 2013, New York University Stern School of Business will convene its faculty thought leaders and some of India’s top corporate leaders and policymakers for a full-day event entitled, “India in the 21st Century: From Potential to Progress

Regus Opens in Cambodia, Expands Footprint to 99 Countries
Regus, the world’s largest provider of flexible workplaces offering a helping hand to local and international businesses in Cambodia, with the launch of its first business centre there

GlaxoSmithKline Pharmaceuticals Net Sales up 10%, PAT before Exceptional Items grows 12% in Third Quarter of FY 2012
GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the third quarter ended 30th September 2012. The growth in Net Sales was 10% and Profit After Tax and before Exceptional Items was 12%. The core Pharmaceuticals business grew by 11% during the quarter. During the quarter, the Company launched Zimivir for herpes treatment

Theravance to Present at the 30th Annual J.P. Morgan Healthcare Conference
Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012, at 9:00 a.m. PST. The conference will be held from January 9-12, 2012 at the Westin St. Francis Hotel in San Francisco, CA.

Dynavax Initiates Proof of Mechanism Trial in Lupus Patients
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the initiation of a proof-of-mechanism clinical trial of the TLR7 and TLR9 inhibitor, DV1179, in systemic lupus erythematosus (SLE) patients. Initiation of this trial entitles Dynavax to receive a $6 million milestone payment from GlaxoSmithKline (GSK) under their worldwide strategic alliance

BrightScope Announces Its Third Annual Year-End Top 30 401k Plans List
BrightScope (www.brightscope.com), the leading provider of independent retirement plan ratings and investment research, is proud to announce the third annual BrightScope Year-End Top 30 Ratings List covering 401k plans with more than $1 billion in assets

Galapagos achieves clinical Proof-of-Mechanism milestone in GSK alliance

Theravance Announces Initiation of Phase 2 Study With Its MARIN Compound, TD-9855, for the Treatment of ADHD
Theravance, Inc. (NASDAQ: THRX) announced today the initiation of an Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 2 study with TD-9855, the lead compound in Theravance's MonoAmine Reuptake INhibitor (MARIN) program

AVI BioPharma Names Jayant Aphale, Ph.D., Senior Vice President of Technical Operations
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced the appointment of Jayant Aphale, Ph.D., as Senior Vice President of Technical Operations effective December 12, 2011. Dr

GlobalEnglish to Host Free Webinar With Leading Expert Charles Jennings on Harnessing the Power of Experiential and Social Learning at Work
GlobalEnglish Corporation (www.GlobalEnglish

Computerworld Announces 2012 Premier 100 Honorees
IDG's Computerworld, the IT media brand dedicated to providing peer perspective, IT leadership and business results, announces the 2012 Premier 100 IT Leaders honorees as well as highlights for the Premier 100 IT Leaders Conference

ProteoTech Announces Drug Development Collaborative Agreement with GlaxoSmithKline for New Parkinson’s Therapeutic
ProteoTech, Inc

WIN Consortium Announces the Scientific Program of WIN 2012 Symposium Where Leaders from Academia, Industry and Regulatory Agencies Will Debate Ways to Improve Efficacy of Cancer Therapeutics in Individual Patients
The 4th WIN Symposium in Personalized Cancer Medicine, to be held in Paris, France, June 28-29, 2012 (WIN 2012), will be again this year the unique forum featuring high-ranking speakers from academia, industry and regulatory agencies worldwide

Comment on this story

Share